Barclays’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.46M | Buy |
72,784
+22,427
| +45% | +$450K | ﹤0.01% | 2433 |
|
|
2025
Q1 | $991K | Sell |
50,357
-14,206
| -22% | -$280K | ﹤0.01% | 2448 |
|
|
2024
Q4 | $1.45M | Buy |
64,563
+8,346
| +15% | +$188K | ﹤0.01% | 2405 |
|
|
2024
Q3 | $1.44M | Buy |
56,217
+42,012
| +296% | +$1.07M | ﹤0.01% | 2405 |
|
|
2024
Q2 | $331K | Sell |
14,205
-12,031
| -46% | -$280K | ﹤0.01% | 2765 |
|
|
2024
Q1 | $462K | Sell |
26,236
-15,842
| -38% | -$279K | ﹤0.01% | 2879 |
|
|
2023
Q4 | $583K | Buy |
42,078
+28,449
| +209% | +$394K | ﹤0.01% | 2917 |
|
|
2023
Q3 | $186K | Sell |
13,629
-1,198
| -8% | -$16.4K | ﹤0.01% | 3068 |
|
|
2023
Q2 | $303K | Buy |
14,827
+7,600
| +105% | +$155K | ﹤0.01% | 2882 |
|
|
2023
Q1 | $158K | Buy |
+7,227
| New | +$158K | ﹤0.01% | 3284 |
|